Shares of Cabaletta Bio, Inc. (CABA) are up nearly 6% at $2.33 in premarket trading on Tuesday.
This late-stage clinical biotechnology company is focused on developing curative targeted cell therapies designed specifically for patients with autoimmune diseases. It's lead Chimeric Antigen Receptor T cell for Autoimmunity (CARTA) candidate, Rese-cel, is being studied in Phase 1/2 clinical trials in systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis and pemphigus vulgaris, dubbed the RESET program.
The RESET program includes multiple ongoing company-sponsored trials like RESET-SLE, RESET-SSc, RESET-MG, and RESET-Myositis, among others.
The company initiated the dermatomyositis (DM) and antisynthetase syndrome (ASyS) registrational cohort of the RESET clinical program last month.
Complete Phase 1/2 clinical data from the RESET-Myositis trial were presented in 2025, with complete Phase 1/2 clinical data from cohorts in RESET-SLE, RESET-SSc and RESET-MG trials anticipated in 1H26.
Rese-cel at a higher dose without preconditioning in patients with pemphigus vulgaris is being evaluated in the RESET-PV trial, with additional durability data from patients dosed at the initial dose and initial clinical data from patients dosed at the higher dose expected in 1H26.
CABA has traded in a range of $0.98 to $3.67 in the last 1 year. The stock closed Friday's trading at $2.20, up 5.77%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.